Glutamate receptor

Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration

Retrieved on: 
Thursday, December 8, 2022

As part of the amended agreement, Indivior will pay Addex an additional USD 1 million to cover additional research activities during this extended period.

Key Points: 
  • As part of the amended agreement, Indivior will pay Addex an additional USD 1 million to cover additional research activities during this extended period.
  • Addex retains exclusive rights to develop its own independent GABAB PAM program and is advancing compounds in Charcot-Marie-Tooth type 1A neuropathy (CMT1A), chronic cough and pain.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates, with a focus on substance use disorder.

Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Retrieved on: 
Thursday, November 3, 2022

53 LR

Key Points: 
  • 53 LR
    Geneva, Switzerland, November 3, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (the Company), announced today that it had received written notification from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for the Companys American Depositary Shares (ADSs) had closed below the minimum US$1.00 per ADS requirement for continued listing on Nasdaq under listing rule 5550(a)(2).
  • Compliance will be achieved if the bid price of the ADSs closes at US$1.00 per ADS or more for a minimum of ten consecutive business days.
  • The Company will monitor the bid price of its ADSs and evaluate options to regain compliance with Nasdaqs minimum bid price rule within the compliance period.
  • The Companys operations are not affected by the receipt of the notification letter and The Company fully intends to resolve the deficiency and regain compliance with the Nasdaq Listing Rules.

Addex Increases Issued Share Capital to Create Treasury Shares

Retrieved on: 
Tuesday, November 1, 2022

The new shares, issued from the Companys authorized capital, are listed on the SIX Swiss Exchange.

Key Points: 
  • The new shares, issued from the Companys authorized capital, are listed on the SIX Swiss Exchange.
  • The total number of issued shares increased to 97,909,428 at a nominal value of CHF 0.01 each, whilst the outstanding shares remain unchanged.
  • 135 FMIA in respect of all listed shares of Addex Therapeutics Ltd in connection with the transaction described in this decision.
  • Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange.

Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference

Retrieved on: 
Tuesday, September 20, 2022

In his presentations, Mr. Dyer will provide a corporate update and discuss recent developments at Addex.

Key Points: 
  • In his presentations, Mr. Dyer will provide a corporate update and discuss recent developments at Addex.
  • A video of each presentation will be available for viewing on-demand by registered participants.
  • Mr. Dyer will also participate in a neurodegenerative diseases roundtable discussion with other panelists at the Sachs Associates Conference, scheduled on September 22, 2022.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.

Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders

Retrieved on: 
Monday, August 15, 2022

As part of the amended agreement, Indivior will provide Addex with CHF 850,000 (approx.

Key Points: 
  • As part of the amended agreement, Indivior will provide Addex with CHF 850,000 (approx.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Addex's second clinical program, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in a range of indications.
  • Indivior PLC has licensed Addexs GABAB PAM program for the development of drug candidates, with a focus on substance use disorder.

Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

Retrieved on: 
Friday, May 27, 2022

A total of 15 patients were enrolled into this double-blind, placebo controlled Phase 2a feasibility study.

Key Points: 
  • A total of 15 patients were enrolled into this double-blind, placebo controlled Phase 2a feasibility study.
  • The primary objective of the study was to evaluate the safety and tolerability of dipraglurant in patients administered with 50mg and 100mg doses.
  • Addex remains committed to our allosteric modulator approach to drug discovery and development with two clinical trials currently ongoing.
  • Addex has been conducting a placebo-controlled Phase 2b/3 pivotal clinical trial of dipraglurant in PD-LID patients since June 2021.

Addex Announces Participation in the H.C. Wainwright Global Investment Conference

Retrieved on: 
Thursday, May 19, 2022

Geneva, Switzerland, May 19, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will be virtually attending the H.C. Wainwright Global Investment Conference taking place May 23 - 26, 2022.

Key Points: 
  • Geneva, Switzerland, May 19, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will be virtually attending the H.C. Wainwright Global Investment Conference taking place May 23 - 26, 2022.
  • Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate update and discusses recent developments at Addex.
  • Mr. Dyer will be available for virtual one-on-one meetings throughout the conference.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.

Addex Announces Participation in the 22nd Bio€quity Europe Conference

Retrieved on: 
Friday, May 13, 2022

Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate update and discusses recent developments at Addex.

Key Points: 
  • Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate update and discusses recent developments at Addex.
  • Mr. Dyer and Dr. Ltjens will be available for one-on-one meetings throughout the conference.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Indivior PLC has licensed Addexs GABAB PAM program for the development of drug candidates with a focus in substance use disorder.

Addex Shareholders Approve All Resolutions at Annual General Meeting

Retrieved on: 
Tuesday, May 10, 2022

53 LR

Key Points: 
  • 53 LR
    Geneva, Switzerland, May 10, 2022 Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all of the proposals of the board of directors in its 2022 Annual General Meeting (AGM).
  • In line with the Swiss Federal Council COVID-19 Ordinance 3, the company decided to require its shareholders not attend the AGM in person.
  • Addex shareholders approved the 2021 annual report, the 2021 annual financial statements, the appropriation of the results as well as the compensation report (the latter in a consultative vote).
  • Addex shareholders approved the amendment of the articles of association concerning the authorized and conditional share capital of the company.

Addex Reports Q1 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022

During the same period, staff costs increased by CHF 0.5 million of which CHF 0.3 million relate to higher share-based compensation costs and CHF 0.2 million relate to additional staff.

Key Points: 
  • During the same period, staff costs increased by CHF 0.5 million of which CHF 0.3 million relate to higher share-based compensation costs and CHF 0.2 million relate to additional staff.
  • R&D expenses consist primarily of costs associated with research, preclinical and clinical testing, and related staff costs.
  • Basic and diluted loss per share increased to CHF 0.15 for the first quarter 2022, compared to CHF 0.08 for the first quarter 2021.
  • Q1 2022 Consolidated Financial Statements:
    Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.